Cartesian Therapeutics (RNAC) Financials: History & Chart

Cartesian Therapeutics, Inc.(RNAC)

Biotechnology · Frederick, MD

$6.81-0.33 (-4.62%)

Delayed quote: Oct 6, 2026, 3:50 PM EDT

About Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

Frederick, MD

75 employees

cartesiantherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Carsten Brunn

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	1.48M	0.00	78K	947K	452K	298K	1.10M	-759K	387K
Cost of Goods Sold	12.80M	0.00	0.00	0.00	12.80M	0.00	0.00	0.00	0.00
Gross Profit	-11.32M	0.00	78K	947K	-12.35M	298K	1.10M	-759K	387K
Gross Profit Margin	-766.4%	N/A	100.0%	100.0%	-2731.2%	100.0%	100.0%	100.0%	100.0%
Total Operating Expenses	87.34M	29.16M	26.58M	22.89M	8.72M	22.11M	22.99M	25.97M	17.96M
Research & Development	68.39M	20.43M	19.46M	14.69M	13.80M	14.87M	14.67M	11.31M	11.40M
Selling, General & Administrative	31.75M	8.72M	7.11M	8.20M	7.72M	7.24M	8.31M	7.09M	6.56M
Operating Income (EBIT)	-98.66M	-29.16M	-26.50M	-21.94M	-21.07M	-21.81M	-21.89M	-26.73M	-17.57M
Operating Margin	-6679.7%	N/A	-33973.1%	-2316.7%	-4660.6%	-7319.1%	-1989.9%	3521.9%	-4541.3%
Income Before Tax (EBT)	-161.08M	15.77M	-39.18M	-101.77M	-35.90M	15.89M	-17.71M	-9.97M	-24.18M
Interest Income	4.95M	1.10M	1.03M	1.27M	1.55M	1.75M	2.02M	7.39M	2.57M
Interest Expense	852K	852K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	-62.42M	44.92M	-12.68M	-79.83M	-14.84M	37.70M	4.18M	16.77M	-6.61M
Net Income	-153.94M	13.72M	-39.18M	-92.58M	-35.90M	15.89M	-17.71M	-10.25M	-24.18M
Income Tax Expense	-9.19M	0.00	0.00	-9.19M	0.00	0.00	0.00	287K	0.00
Net Profit Margin	-10422.5%	N/A	-50233.3%	-9775.7%	-7942.9%	5330.9%	-1610.0%	1350.9%	-6248.8%
EBITDA	-96.03M	-28.36M	-25.88M	-21.33M	-20.46M	-21.22M	-20.73M	-26.25M	-17.29M
EBITDA Margin	-6501.7%	N/A	-33184.6%	-2252.5%	-4526.5%	-7121.5%	-1884.8%	3457.8%	-4467.4%
Depreciation & Amortization	2.63M	800K	615K	608K	606K	589K	1.16M	486K	286K
EPS Basic	-5.93	0.47	-1.46	-3.56	-1.38	0.61	-0.68	-0.07	-1.13
EPS Diluted	-5.84	0.46	-1.46	-3.46	-1.38	0.60	-0.68	-0.07	-1.13
Weighted Average Basic Shares	29.47M	29.47M	26.86M	25.97M	26.00M	25.98M	25.90M	25.91M	21.47M
Weighted Average Diluted Shares	29.86M	29.86M	26.86M	25.97M	26.00M	26.45M	25.90M	25.91M	21.47M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	2.80M	38.91M	26.00M	110.78M	85.08M	16.60M	6.68M	903K
Cost of Goods Sold	0.00	0.00	0.00	2.04M	0.00	0.00	0.00	0.00
Gross Profit	2.80M	38.91M	26.00M	108.74M	85.08M	16.60M	6.68M	903K
Gross Profit Margin	100.0%	100.0%	100.0%	98.2%	100.0%	100.0%	100.0%	100.0%
Total Operating Expenses	89.50M	82.81M	112.42M	94.20M	89.67M	73.42M	59.13M	64.95M
Research & Development	58.03M	45.10M	71.26M	72.38M	68.74M	54.51M	42.74M	47.69M
Selling, General & Administrative	31.47M	30.13M	40.45M	23.86M	20.94M	18.91M	16.39M	17.26M
Operating Income (EBIT)	-86.70M	-43.90M	-86.42M	14.54M	-4.60M	-56.82M	-52.45M	-65.02M
Operating Margin	-3099.9%	-112.8%	-332.3%	13.1%	-5.4%	-342.4%	-785.6%	-7200.7%
Income Before Tax (EBT)	-139.50M	-77.14M	-238.71M	34.77M	-9.72M	-68.88M	-55.35M	-65.34M
Interest Income	6.58M	7.39M	4.96M	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	2.83M	3.03M	2.84M	1.56M	1.52M	1.49M
Other Income/Expense	-52.79M	-33.24M	-152.29M	20.23M	-5.12M	-12.05M	-2.90M	-314K
Net Income	-130.30M	-77.42M	-219.71M	35.38M	-25.69M	-68.88M	-55.35M	-65.34M
Income Tax Expense	-9.19M	287K	-19.00M	-609K	15.97M	0.00	0.00	0.00
Net Profit Margin	-4658.6%	-199.0%	-844.9%	31.9%	-30.2%	-415.0%	-829.0%	-7235.4%
EBITDA	-83.75M	-42.75M	-85.57M	16.57M	-2.88M	-55.09M	-50.43M	-64.05M
EBITDA Margin	-2994.1%	-109.9%	-329.1%	15.0%	-3.4%	-332.0%	-755.2%	-7092.7%
Depreciation & Amortization	2.96M	1.15M	843K	2.04M	1.72M	1.73M	2.03M	975K
EPS Basic	-5.02	-3.29	-49.76	7.33	-6.74	-20.42	-36.46	-87.55
EPS Diluted	-5.02	-3.29	-49.76	N/A	-6.60	-20.42	-36.46	-87.55
Weighted Average Basic Shares	25.97M	23.69M	5.17M	4.02M	3.18M	2.81M	1.27M	622K
Weighted Average Diluted Shares	25.97M	23.69M	5.17M	4.05M	3.18M	2.81M	1.27M	622K

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.